About this Research Topic
The field of cancer immunotherapy has been significantly challenged by the presence of tumor-associated myeloid cells, which include macrophages, regulatory myeloid dendritic cells, and immature myeloid suppressor cells (MDSCs). These cells are known to contribute to immune dysfunction, thereby hindering the effectiveness of current cancer treatments. Despite extensive research, the precise mechanisms that dictate the differentiation, expansion, and function of these myeloid cells within the tumor microenvironment remain elusive. Recent studies have highlighted the complexity and heterogeneity of these cells, emphasizing the need for a deeper understanding of their biology. While some progress has been made in identifying the signaling pathways and transcriptional networks involved, there is still a significant gap in translating this knowledge into effective therapeutic strategies. Addressing these gaps is crucial for the development of novel interventions that can reprogram myeloid cells to enhance antitumor immunity.
This research topic aims to explore the underlying mechanisms that regulate the biology of tumor-associated myeloid cells and to identify innovative therapeutic strategies that can reprogram these cells to support effective cancer immunotherapy. By investigating the cellular and molecular processes that govern the behavior of these myeloid cells, the research seeks to answer critical questions about their role in tumor progression and resistance to treatment. The ultimate goal is to develop approaches that can either reduce the abundance of these cells or alter their function to promote robust antitumor immune responses.
To gather further insights into the differentiation and reprogramming of tumor-associated myeloid cells, we welcome articles addressing, but not limited to, the following themes:
- Studies on cellular processes governing the plasticity and physiology of tumor-associated myeloid cells, including migration, metabolic regulation, and cell cycle control.
- Exploration of molecular events, signaling cascades, and transcriptional networks that promote the differentiation and expansion of tumor-associated myeloid cells.
- Phenotypic and functional characterizations of cancer-associated myeloid cells in both murine models and human cancer specimens.
- Novel approaches aimed at reducing their abundance or reprogramming these cells to stimulate innate and adaptive antitumor immune responses.
- Evaluation of the biomarker value and mechanisms associated with drug resistance mediated by tumor-associated myeloid cells.
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
This research topic aims to explore the underlying mechanisms that regulate the biology of tumor-associated myeloid cells and to identify innovative therapeutic strategies that can reprogram these cells to support effective cancer immunotherapy. By investigating the cellular and molecular processes that govern the behavior of these myeloid cells, the research seeks to answer critical questions about their role in tumor progression and resistance to treatment. The ultimate goal is to develop approaches that can either reduce the abundance of these cells or alter their function to promote robust antitumor immune responses.
To gather further insights into the differentiation and reprogramming of tumor-associated myeloid cells, we welcome articles addressing, but not limited to, the following themes:
- Studies on cellular processes governing the plasticity and physiology of tumor-associated myeloid cells, including migration, metabolic regulation, and cell cycle control.
- Exploration of molecular events, signaling cascades, and transcriptional networks that promote the differentiation and expansion of tumor-associated myeloid cells.
- Phenotypic and functional characterizations of cancer-associated myeloid cells in both murine models and human cancer specimens.
- Novel approaches aimed at reducing their abundance or reprogramming these cells to stimulate innate and adaptive antitumor immune responses.
- Evaluation of the biomarker value and mechanisms associated with drug resistance mediated by tumor-associated myeloid cells.
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
Keywords: Tumor-associated myeloid cells, DCs, macrophages, immature, Antitumor immunity, Signaling pathways, Immune dysfunction, Cancer immunotherapy
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
